Sound Pharmaceuticals raises $30M to advance SPI-1005 (Ebselen) into mid/late trials for noise-induced hearing loss

Sound Pharmaceuticals is raising $30 million (with just over $4 million committed so far) to fund mid- and late-stage trials of SPI-1005, an Ebselen-containing drug aimed at preventing or reversing noise-induced hearing loss. Ebselen can enter the cochlea and cross the blood-brain barrier, so SPI-1005 is being advanced for hearing loss while the compound is also studied for other ear disorders and bipolar disorder.

No comments yet.